A New Era of Cancer Therapy Has Begun
Jeffrey Martin, Founder
- Video
A new era in cancer therapy is here. Multispecific protein therapeutics, mainly appearing in the form of bispecific antibodies, are poised to completely transform the oncology landscape. With major players like Summit Therapeutics, AbbVie, BioNTech, and even Merck racing to innovate, the fight for the future of cancer treatment is intensifying.
The "Hidden Advantage" Of In-Vivo CAR-T
Jeffrey Martin, Founder
- Video
In Vivo CAR-T, or the generation of CAR-T cells via the delivery of a CAR-expressing gene therapy, has officially arrived in oncology. There is a lot of buzz surrounding the technology because it promises to overcome many of the clinical limitations of traditional CAR technology. However, there is a hidden advantage of in vivo CAR that not many people are talking about and it might change the game when it comes to solid tumors. Find out more in this video.
Don't Underestimate This NK Cell Engager
Jeffrey Martin, Founder
- Video
Everyone in oncology is absolutely obsessed with T cells – and for good reason. When a T cell becomes activated, it expands like crazy and becomes highly cytotoxic, making them perfect therapeutic foot soldiers. As a result, other cells like NK cells have historically taken a back seat.
